SCHEMBL8558191

SCHEMBL8558191

Cc1cc[c]c(C2CCNCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.50
SLC6A2 P23975 4/20 0.38
SLC6A4 P31645 4/20 0.38
SLC6A3 Q01959 3/20 0.38
HTR1A P08908 2/20 0.38
SLC18A3 Q16572 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
MEN1 O00255 1/20 0.37
CYP2D6 P10635 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR6 P50406 2/20 0.36
QDPR P09417 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457257 0.87 HTR2C (0.32) HTR2C
SCHEMBL9330891 0.83 NPC1 (0.36) HTR2C
SCHEMBL28119904 0.83 NPC1 (0.33) HTR2C
SCHEMBL1777247 0.81 NPC1 (0.38) KMT2A
SCHEMBL2097686 0.80 QDPR (0.49) HTR2CSLC18A3SIGMAR1HTR6QDPR
SCHEMBL5106428 0.79 HTR3A (0.41) HTR2CSLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL27657802 0.79 SLC6A2 (0.39) HTR2CSLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL28108546 0.76 SLC6A2 (0.39) HTR2CSLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL27657806 0.73 HTR2C (0.43) HTR2CSLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL999284 0.72 SLC18A3 (0.50) HTR2CSLC6A2SLC6A4SLC6A3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1972911-A 2-(1h-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence LUNDBECK & CO AS H (DK) 2007-05-30 CN disclosed
EP-0832076-A1 NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-04-01 EP disclosed